Healthy Skepticism Library item: 7252

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

JNJ: New Labelling Could Reduce Tylenol Sales
Yahoo Finance 2006 Dec 21
http://biz.yahoo.com/seekingalpha/061221/22806_id.html?.v=1

Abstract:

Johnson & Johnson said that Tylenol sales might drop following new FDA labeling regulations for the OTC analgesic. Tylenol labels will be required to to warn patients about the risk of liver damage when taken in high doses or with alcohol. Previously, the drug had been considered safer than its competitors Advil (ibuprofen) and aspirin, especially after the FDA determined that they might have the same cardiovascular risks as Vioxx. Tylenol sales increased about 10% in 2005 from the previous year. The new labeling will also affect generic forms of acetaminophen, Tylenol’s main ingredient. Analysts are still not sure how the new labeling will affect Tylenol sales. McNeil Consumer Healthcare, the JNJ subsidiary that markets Tylenol, was responsible for $2.1 billion of company’s overall $47 billion in 2004 sales. Therefore, analysts don’t expect a sales drop to dramatically impact JNJ’s performance.

Please
Click to Register

(read more)

then
Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Announcements

PharmedOut’s annual conference: Missing The Target: When Practitioners Harm More Than Heal

No Free Lunch is merging with Healthy Skepticism

Conference program: Pharma Knows Best? Managing Medical Knowledge

Prescrire’s proposals for France’s national conference on medicines policy

Pharmed Out Conference ‘Pharma Knows Best? Managing Medical Knowledge’

More announcements

What's new on this site

Library Home

Library Search

Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909